Characteristics of HIV-1 Seropositive Individuals
| . | LTA* n = 18 . | PROG* n = 42 . | AIDS-NHL* n = 30 . |
|---|---|---|---|
| Age† | 41 (30-51) | 38 (24-55) | 36 (24-57) |
| Follow-up‡ | 148 (102-164) | 54 (26-109) | 49 (12-144) |
| Seroconverted1-153 | 5 | 16 | 1 |
| Seroprevalent1-155 | 13 | 26 | 29 |
| CD4+ T cells1-154 | 560 (250-970) | 400 (30-1260) | 470 (10-960) |
| . | LTA* n = 18 . | PROG* n = 42 . | AIDS-NHL* n = 30 . |
|---|---|---|---|
| Age† | 41 (30-51) | 38 (24-55) | 36 (24-57) |
| Follow-up‡ | 148 (102-164) | 54 (26-109) | 49 (12-144) |
| Seroconverted1-153 | 5 | 16 | 1 |
| Seroprevalent1-155 | 13 | 26 | 29 |
| CD4+ T cells1-154 | 560 (250-970) | 400 (30-1260) | 470 (10-960) |
LTA, long-term asymptomatic individuals; PROG, progressors to AIDS-OI or AIDS-KS and AIDS-NHL, progressors developing NHL.
Age, median (range) in years at time of EBV-type analysis.
Follow-up, median (range) seropositive time (months) in study until the ninth year for LTA or AIDS-diagnosis for progressors.
Seroconverted, number of individuals that seroconverted during follow-up.
Seroprevalent, number of individuals that were already HIV-1 seropositive when they entered the study.
CD4+ T cells, median (range) CD4+ T-cell numbers at EBV-type analysis (for progressors in the last year before AIDS diagnosis, for LTA in the ninth year of follow-up).